Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy

This study assessed the efficacy and safety of baricitinib in five patients with severe alopecia areata (AA) and coexisting psoriasis and/or psoriatic arthritis (PsA). Over 52 weeks, baricitinib led to complete AA remission in one patient and significant improvement in two others, with mean SALT scores decreasing from 83 to 8.75. Psoriasis remained stable, with mean PASI scores improving from 1.4 to 0.5. However, one patient with PsA experienced worsening symptoms and discontinued treatment. The findings suggest baricitinib is effective for AA and may benefit psoriasis, but it may not be optimal for PsA, indicating a need for further research in multi-immune diseases.